{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.0","upperLimit":"8.5","value":"5.5"},{"groupId":"OG001","lowerLimit":"1.25","upperLimit":"2.73","value":"1.4"},{"groupId":"OG002","lowerLimit":"1.8","upperLimit":"15.4","value":"4.5"},{"groupId":"OG003","lowerLimit":"1.45","upperLimit":"5.45","value":"2.8"},{"groupId":"OG004","lowerLimit":"1.3","upperLimit":"2.9","value":"2.4"},{"groupId":"OG005","lowerLimit":"1.4","upperLimit":"2.7","value":"2.4"},{"groupId":"OG006","lowerLimit":"1.5","upperLimit":"2.8","value":"2.8"},{"groupId":"OG007","lowerLimit":".07","upperLimit":".07","value":".07"},{"comment":"There was only one out of three subjects evaluated; unable to estimate due to insufficient number of patients within cohort.","groupId":"OG008","lowerLimit":"2.3","upperLimit":"NA","value":"NA"},{"groupId":"OG009","lowerLimit":".72","upperLimit":"1.38","value":"1.0"},{"groupId":"OG010","lowerLimit":"1.3","upperLimit":"6.8","value":"2.5"},{"groupId":"OG011","lowerLimit":"1.3","upperLimit":"4.2","value":"1.4"},{"groupId":"OG012","lowerLimit":"1.9","upperLimit":"6.9","value":"5.5"},{"groupId":"OG013","lowerLimit":".85","upperLimit":"2.23","value":"1.5"},{"groupId":"OG014","lowerLimit":"3.9","upperLimit":"13.6","value":"4.9"},{"groupId":"OG015","lowerLimit":"1.3","upperLimit":"1.6","value":"1.4"},{"groupId":"OG016","lowerLimit":"5.1","upperLimit":"13.5","value":"6.9"},{"groupId":"OG017","lowerLimit":".7","upperLimit":"1.3","value":"1.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"12"},{"groupId":"OG012","value":"8"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"7"},{"groupId":"OG015","value":"6"},{"groupId":"OG016","value":"5"},{"groupId":"OG017","value":"5"}],"units":"Participants"}],"description":"Progression Free Survival during the Randomized Stage (Randomized Population)","dispersionType":"95% Confidence Interval","groups":[{"description":"cabozantinib, 100 mg, po QD, ongoing until progression","id":"OG000","title":"Randomized Phase - CRPC, Cabozantinib Arm"},{"description":"placebo 100mg, po QD, ongoing until progression","id":"OG001","title":"Randomized Phase - CRPC, Placebo Arm"},{"description":"cabozantinib, 100 mg, po QD, ongoing until progression","id":"OG002","title":"Randomized Phase - Melanoma, Cabozantinib Arm"},{"description":"Placebo, 100mg, po QD, ongoing until progression","id":"OG003","title":"Randomized Phase - Melanoma, Placebo Arm"},{"description":"cabozantinib, 100 mg, po QD, ongoing until progression","id":"OG004","title":"Randomized Phase - NSCLC, Cabozantinib Arm"},{"description":"placebo, 100mg, po QD, ongoing until progression","id":"OG005","title":"Randomized Phase - NSCLC, Placebo Arm"},{"description":"cabozantinib, 100 mg, po QD, ongoing until progression","id":"OG006","title":"Randomized Phase - Pancreatic Cancer, Cabozantinib Arm"},{"description":"placebo, 100mg, po QD, ongoing until progression","id":"OG007","title":"Randomized Phase - Pancreatic Cancer, Placebo Arm"},{"description":"cabozantinib, 100 mg, po QD, ongoing until progression","id":"OG008","title":"Randomized Phase - Gastric/GEJ, Cabozantinib Arm"},{"description":"placebo, 100mg, po QD, ongoing until progression","id":"OG009","title":"Randomized Phase - Gastric/GEJ , Placebo Arm"},{"description":"cabozantinib, 100 mg, po QD, ongoing until progression","id":"OG010","title":"Randomized Phase - HCC, Cabozantinib Arm"},{"description":"placebo, 100 mg, po QD, ongoing until progression","id":"OG011","title":"Randomized Phase - HCC, Placebo Arm"},{"description":"cabozantinib, 100 mg, po QD, ongoing until progression","id":"OG012","title":"Randomized Phase - SCLC, Cabozantinib Arm"},{"description":"placebo, 100 mg, po QD, ongoing until progression","id":"OG013","title":"Randomized Phase - SCLC, Placebo Arm"},{"description":"cabozantinib, 100 mg, po QD, ongoing until progression","id":"OG014","title":"Randomized Phase - Ovarian Cancer, Cabozantinib Arm"},{"description":"placebo, 100 mg, po QD, ongoing until progression","id":"OG015","title":"Randomized Phase - Ovarian Cancer, Placebo Arm"},{"description":"cabozantinib, 100 mg, po QD, ongoing until progression","id":"OG016","title":"Randomized Phase - MBC, Cabozantinib Arm"},{"description":"placebo, 100 mg, po QD, ongoing until progression","id":"OG017","title":"Randomized Phase - MBC, Placebo Arm"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From initial dose through final study visit up to 44 months","title":"Progression-Free Survival (PFS) - Randomized Stage, RDT Cohorts Only","type":"PRIMARY","unitOfMeasure":"months"}